Skip to main content

BioFactura Awarded $1 Million SBIR Contract for Development of a Marburg Virus Therapeutic

By August 3, 2020News
BioFactura Logo

BioFactura Logo

FREDERICK, Md., July 29, 2020 /PRNewswire-PRWeb/ — BioFactura, Inc. today announced a $1 million Small Business Innovation Research (SBIR) Phase II contract awarded by the Joint Science & Technology Office—Chemical and Biological Defense (JSTO-CBD) of the Department of Defense (DoD). The goal of this project is to develop, optimize, and scale-up a highly efficient mammalian cell culture-based bioprocess suitable to meet surge requirement needs for rapid manufacture of a monoclonal antibody (mAb) therapeutic against the Marburg virus (MARV) biothreat.

 

{iframe}https://finance.yahoo.com/news/biofactura-awarded-1-million-sbir-120000838.html{/iframe}

Leave a Reply

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.